Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi‐Long Wu(Guangdong General Hospital), Caicun Zhou(Shanghai Pulmonary Hospital), Chengping Hu(Xiangya Hospital Central South University), Jifeng Feng, Shun Lü(Shanghai Jiao Tong University), Yunchao Huang(Kunming Medical University), Wěi Li(First Hospital of Jilin University), Mei Hou(Sichuan University), Jian Hua Shi(Linyi People's Hospital), Kye Young Lee(Konkuk University Medical Center), Chong‐Rui Xu(Guangdong Academy of Medical Sciences), Dan Massey(Boehringer Ingelheim (United Kingdom)), Miyoung Kim(Boehringer Ingelheim (South Korea)), Yang Shi(Boehringer Ingelheim (China)), Sarayut Lucien Geater(Prince of Songkla University)
Cited by 1,972
Abstract
Related Papers
No related papers found
Powered by citation graph analysis